Skip to main content
. 2021 Jul 31;13(15):3869. doi: 10.3390/cancers13153869

Figure 6.

Figure 6

Kaplan–Meier estimates of the relapse-free survival of metastatic breast cancer patients with K16+ CTCs (black dashed line) and K16− CTCs (solid gray line). Statistical significance was determined by a log-rank test. Shorter relapse-free survival correlates with the presence of K16+ CTCs in the blood (p = 0.0042).